CO2021007691A2 - Anticuerpos monoclonales antagonistas contra cd40 y sus usos - Google Patents
Anticuerpos monoclonales antagonistas contra cd40 y sus usosInfo
- Publication number
- CO2021007691A2 CO2021007691A2 CONC2021/0007691A CO2021007691A CO2021007691A2 CO 2021007691 A2 CO2021007691 A2 CO 2021007691A2 CO 2021007691 A CO2021007691 A CO 2021007691A CO 2021007691 A2 CO2021007691 A2 CO 2021007691A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- monoclonal antibodies
- antibodies against
- activity
- antagonist monoclonal
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 101150013553 CD40 gene Proteins 0.000 abstract 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940123189 CD40 agonist Drugs 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La divulgación proporciona anticuerpos que se fijan a CD40, que incluyen un anticuerpo humanizado. Los anticuerpos se fijan a CD40 y no exhiben actividad agonista de CD40. Los anticuerpos pueden comprender un dominio Fc de IgG1 modificado y exhibir activación mínima de células dendríticas inmaduras. Se proporcionan composiciones que comprenden anticuerpos, métodos de uso para el tratamiento de enfermedades que incluyen la actividad de CD40, y el uso en la preparación de un medicamento para el tratamiento de una enfermedad que incluyen la actividad de CD40.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862769514P | 2018-11-19 | 2018-11-19 | |
PCT/US2019/062011 WO2020106620A1 (en) | 2018-11-19 | 2019-11-18 | Antagonistic cd40 monoclonal antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021007691A2 true CO2021007691A2 (es) | 2021-09-20 |
Family
ID=68848451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0007691A CO2021007691A2 (es) | 2018-11-19 | 2021-06-11 | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
Country Status (19)
Country | Link |
---|---|
US (6) | US11261258B2 (es) |
EP (1) | EP3883652A1 (es) |
JP (2) | JP7271666B2 (es) |
KR (1) | KR102627246B1 (es) |
CN (2) | CN116003608B (es) |
AR (1) | AR117091A1 (es) |
AU (1) | AU2019385331A1 (es) |
BR (1) | BR112021009140A2 (es) |
CA (1) | CA3120358C (es) |
CL (1) | CL2021001230A1 (es) |
CO (1) | CO2021007691A2 (es) |
EA (1) | EA202191359A1 (es) |
IL (1) | IL283104A (es) |
MX (1) | MX2021005565A (es) |
PE (1) | PE20211293A1 (es) |
SG (1) | SG11202104776VA (es) |
TW (1) | TWI800694B (es) |
WO (1) | WO2020106620A1 (es) |
ZA (1) | ZA202103353B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR111830A1 (es) | 2017-05-25 | 2019-08-21 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
WO2022046942A1 (en) * | 2020-08-25 | 2022-03-03 | Bristol-Myers Squibb Company | Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies |
KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
CN115812082A (zh) * | 2021-07-14 | 2023-03-17 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
TW202340256A (zh) * | 2022-04-02 | 2023-10-16 | 大陸商和鉑醫藥(上海)有限責任公司 | 一種標靶cd40的抗原結合蛋白及其製備和應用 |
CN117264063B (zh) * | 2023-03-22 | 2024-04-23 | 赛业(苏州)生物科技有限公司 | 一种抗gpc3抗体及其应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB2353887B (en) | 1999-09-04 | 2003-09-24 | Ibm | Speech recognition system |
WO2003028809A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Methods of therapy for b-cell malignancies |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
JP4746552B2 (ja) * | 2003-11-04 | 2011-08-10 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗cd40抗体の使用 |
US20070218060A1 (en) * | 2003-11-04 | 2007-09-20 | Chiron Corporation | Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma |
DK1682177T3 (da) * | 2003-11-04 | 2010-11-01 | Novartis Vaccines & Diagnostic | Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi |
EP1761311A2 (en) * | 2004-04-27 | 2007-03-14 | Novartis Vaccines and Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
CN101014619B (zh) | 2004-07-15 | 2010-11-03 | 赞科股份有限公司 | 优化的Fc变体 |
US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
US20150315284A1 (en) | 2004-11-09 | 2015-11-05 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
WO2007047578A2 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
WO2008091954A2 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
EP2614837A1 (en) | 2007-11-09 | 2013-07-17 | Affitech Research AS | Anti-VEGF antibody compositions and methods |
US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
KR101760242B1 (ko) | 2010-03-31 | 2017-07-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-cd40 항체 |
US9303083B2 (en) | 2010-10-04 | 2016-04-05 | Riken | Therapeutic agent for malignant tumors expressing MHC class II |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
TW201245225A (en) | 2011-04-21 | 2012-11-16 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize CD40 |
CN106928362B (zh) * | 2011-04-29 | 2021-10-26 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
RU2014117505A (ru) | 2011-09-30 | 2015-11-10 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула для ускорения удаления антигенов |
CN113480639A (zh) | 2012-02-09 | 2021-10-08 | 中外制药株式会社 | 抗体的Fc区变异体 |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
JP6514103B2 (ja) | 2012-07-06 | 2019-05-15 | ゲンマブ ビー.ブイ. | 三重変異を有する二量体タンパク質 |
TW202340236A (zh) | 2012-08-24 | 2023-10-16 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
ES2879552T3 (es) * | 2012-10-30 | 2021-11-22 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
JP6598680B2 (ja) | 2013-04-02 | 2019-10-30 | 中外製薬株式会社 | Fc領域改変体 |
GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
LT3177643T (lt) | 2014-08-04 | 2019-08-12 | F. Hoffmann-La Roche Ag | T ląstelę aktyvinantį antigeną surišančios bispecifinės molekulės |
WO2016023875A1 (en) * | 2014-08-14 | 2016-02-18 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
PE20170782A1 (es) | 2014-11-21 | 2017-07-04 | Bristol Myers Squibb Co | Anticuerpos frente a cd73 y usos de los mismos |
AU2016270640B2 (en) * | 2015-05-29 | 2022-03-10 | Abbvie Inc. | Anti-CD40 antibodies and uses thereof |
CA2990012A1 (en) * | 2015-06-29 | 2017-01-05 | Bristol-Myers Squibb Company | Antibodies to cd40 |
AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
CA3000400A1 (en) | 2015-09-30 | 2017-04-06 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding human cd40 and methods of use |
SG11201901468SA (en) | 2016-10-06 | 2019-03-28 | Glaxosmithkline Ip Dev Ltd | Antibodies with reduced binding to process impurities |
SG11201907848YA (en) | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
WO2018175279A2 (en) | 2017-03-20 | 2018-09-27 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
US20200148779A1 (en) | 2017-05-25 | 2020-05-14 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
EP3630833A1 (en) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
AR111830A1 (es) | 2017-05-25 | 2019-08-21 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
EP3704158A1 (en) | 2017-11-03 | 2020-09-09 | Novartis AG | Anti-cd40 antibodies for use in treatment of sjögren's syndrome |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
US20220106400A1 (en) | 2018-11-28 | 2022-04-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
-
2019
- 2019-11-15 AR ARP190103362A patent/AR117091A1/es unknown
- 2019-11-18 EA EA202191359A patent/EA202191359A1/ru unknown
- 2019-11-18 WO PCT/US2019/062011 patent/WO2020106620A1/en active Application Filing
- 2019-11-18 CA CA3120358A patent/CA3120358C/en active Active
- 2019-11-18 EP EP19818398.0A patent/EP3883652A1/en active Pending
- 2019-11-18 CN CN202310098945.0A patent/CN116003608B/zh active Active
- 2019-11-18 AU AU2019385331A patent/AU2019385331A1/en active Pending
- 2019-11-18 BR BR112021009140-8A patent/BR112021009140A2/pt unknown
- 2019-11-18 PE PE2021000727A patent/PE20211293A1/es unknown
- 2019-11-18 US US16/686,596 patent/US11261258B2/en active Active
- 2019-11-18 KR KR1020217018573A patent/KR102627246B1/ko active IP Right Grant
- 2019-11-18 MX MX2021005565A patent/MX2021005565A/es unknown
- 2019-11-18 SG SG11202104776VA patent/SG11202104776VA/en unknown
- 2019-11-18 CN CN201980076479.8A patent/CN113164781B/zh active Active
- 2019-11-18 JP JP2021527208A patent/JP7271666B2/ja active Active
- 2019-11-19 TW TW108142021A patent/TWI800694B/zh active
-
2020
- 2020-10-26 US US17/080,626 patent/US11254750B2/en active Active
-
2021
- 2021-05-11 CL CL2021001230A patent/CL2021001230A1/es unknown
- 2021-05-11 IL IL283104A patent/IL283104A/en unknown
- 2021-05-18 ZA ZA2021/03353A patent/ZA202103353B/en unknown
- 2021-06-11 CO CONC2021/0007691A patent/CO2021007691A2/es unknown
-
2022
- 2022-01-19 US US17/579,468 patent/US11926673B2/en active Active
- 2022-01-31 US US17/588,518 patent/US11773178B2/en active Active
- 2022-02-11 US US17/670,223 patent/US11795231B2/en active Active
-
2023
- 2023-04-26 JP JP2023072027A patent/JP2023106402A/ja active Pending
- 2023-08-22 US US18/453,691 patent/US20240124597A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021007691A2 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
PE20200485A1 (es) | Proteinas de union a antigenos trem2 y usos de estas | |
AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
CO2020000438A2 (es) | Anticuerpos anti-ctla-4 y sus usos | |
PE20181349A1 (es) | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador | |
AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
NI201300051A (es) | Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer. | |
CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
BR112014007426A2 (pt) | anticorpos contra tl 1a e seus usos | |
CL2018000819A1 (es) | Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso | |
CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
BR112013027829A2 (pt) | anticorpos anti-cd40 e método de uso | |
CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
CO2021012719A2 (es) | Métodos para producción de células car-nk y uso de las mismas | |
ECSP20063690A (es) | Anticuerpos | |
CL2020003348A1 (es) | Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes | |
AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
CO2022006014A2 (es) | Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas | |
CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
BR112022009482A2 (pt) | Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo | |
EA201892071A1 (ru) | Способ профилактики болезни "трансплантат против хозяина" | |
CL2022001461A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |